Mercury Pharmaceuticals

We are de-risking biomedical innovations, while turning biomedical knowledge into social and economic value.

Stay Informed!

Scientists map 239 human-infective RNA viruses to track future outbreak risks

26

Apr 2026

Scientists map 239 human-infective RNA viruses to track future outbreak risks

Researchers updated the global catalogue of human-infective RNA viruses to 239 ICTV-recognised species, incorporating taxonomy, discovery dates, locations, genome links, host range, transmissibility, and transmission routes. The dataset shows that most known human-infective RNA viruses remain strictly zoonotic, while only a minority are endemic in humans or capable of epidemic spread.

Blue Zones longevity claims may rest on flawed records, essay argues

26

Apr 2026

Blue Zones longevity claims may rest on flawed records, essay argues

Essay challenges the scientific validity of the Blue Zones concept and Ancel Keys’ Lipid Hypothesis, arguing that both rest on biased data, weak records, and methodological flaws. The authors say some longevity claims may reflect clerical errors, poverty, and unreliable vital records rather than uniquely healthy lifestyles.

Scientists will probe whether processing itself makes ultra-processed foods harmful

26

Apr 2026

Scientists will probe whether processing itself makes ultra-processed foods harmful

A randomized controlled trial protocol will test whether the cardiometabolic risks linked to ultra-processed foods stem from industrial processing, poor nutrient composition, or both. Using four controlled diets, researchers will separate the effects of UPF content from saturated fat, added sugar, and sodium on LDL cholesterol, insulin resistance, and blood pressure.

Experts debate benefits and costs of robotic lung transplantation

25

Apr 2026

Experts debate benefits and costs of robotic lung transplantation

The expanding use of robotic technology in lung transplantation came under scrutiny at today's 46th Annual Meeting and Scientific Sessions of the International Society for Heart and Lung Transplantation (ISHLT), where experts debated whether its clinical benefits justify the cost and complexity.

Pediatric heart transplant demand rises amid severe donor shortage

25

Apr 2026

Pediatric heart transplant demand rises amid severe donor shortage

Advances in pediatric heart care are helping more children survive long enough to receive a transplant-but a critical shortage of donor hearts means too many are still dying while they wait, experts warned today at the International Society for Heart and Lung Transplantation (ISHLT) 46th Annual Meeting and Scientific Sessions.

Global debate continues over fair allocation of donor hearts

25

Apr 2026

Global debate continues over fair allocation of donor hearts

As demand for heart transplants continues to far exceed the number of available donor hearts, experts at today's 46th Annual Meeting and Scientific Sessions of the International Society for Heart and Lung Transplantation (ISHLT) explored a critical question: how should this scarce, life-saving resource be allocated?

New cytometer measures cell stiffness to improve disease diagnosis

25

Apr 2026

New cytometer measures cell stiffness to improve disease diagnosis

Researchers from Brown University and their collaborators have developed a new way to measure the properties of cells - an important development, they say, because accurate measurements of changes in cell elasticity can be used to better understand diseases, diagnose patient symptoms and provide more accurate prognoses.

MERCURY trials

Clinical trials are very important as it allow us to evaluate the effectiveness of new drugs, new devices, preventative strategies or treatment strategies. It also enables us to discover better ways for patients' care.
- Learn more

Cancer

Our mission remains constant as we endeavor to deliver novel medicines to patients with cancer, treating solid tumors with high unmet medical needs in well-defined patient populations that are currently not well supported.
- Learn more

Neuroscience

Whether you're looking to manufacture toxicology batches or cGMP material for clinical trials, we can help you expedite molecules to clinic with full transparency.
- Learn more

Mercury Pharmaceuticals

Why Us?

Strong experience in academic research and technology transfer makes us understand your goals and motivations as a technology originator.
Our experience in drug development from discovery to clinical and commercial stages makes us an insider player within the biopharmaceutical industry.
Smart approach to project management that helps speed up development stages and decision making.
Availability of own investment up to 2m€ per project allows us to reach the next value milestone.